Vivek Khemka

763 total citations
23 papers, 519 citations indexed

About

Vivek Khemka is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vivek Khemka has authored 23 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vivek Khemka's work include Cancer Genomics and Diagnostics (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Vivek Khemka is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Vivek Khemka collaborates with scholars based in United States, Spain and Italy. Vivek Khemka's co-authors include Glen J. Weiss, Howard B. Urnovitz, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Ashish Sangal, Cynthia A. Lynch, Jiaxin Niu, John Farley and Ekkehard Schütz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Vivek Khemka

21 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vivek Khemka United States	8	371	142	120	104	71	23	519
Jindřich Kopecký Czechia	13	227 0.6×	79 0.6×	62 0.5×	168 1.6×	106 1.5×	57	474
Zaida Morante Peru	11	266 0.7×	142 1.0×	113 0.9×	140 1.3×	149 2.1×	38	479
Xuewei Zhuang China	11	147 0.4×	123 0.9×	163 1.4×	64 0.6×	201 2.8×	26	460
Thomas Newsom-Davis United Kingdom	12	204 0.5×	53 0.4×	128 1.1×	112 1.1×	233 3.3×	42	516
Romano Scalerta Italy	9	176 0.5×	96 0.7×	77 0.6×	72 0.7×	92 1.3×	16	372
Αngeliki Andrikopoulou Greece	13	220 0.6×	78 0.5×	30 0.3×	89 0.9×	158 2.2×	41	438
Edoardo Crimini Italy	13	268 0.7×	146 1.0×	39 0.3×	117 1.1×	129 1.8×	39	474
Boyd Mudenda United States	10	270 0.7×	53 0.4×	47 0.4×	86 0.8×	98 1.4×	20	435
Sidrah Shah United Kingdom	9	168 0.5×	102 0.7×	31 0.3×	97 0.9×	128 1.8×	11	371
Sakarias Wangefjord Sweden	12	256 0.7×	109 0.8×	42 0.3×	61 0.6×	177 2.5×	17	500

Countries citing papers authored by Vivek Khemka

Since Specialization

Citations

This map shows the geographic impact of Vivek Khemka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Khemka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Khemka more than expected).

Fields of papers citing papers by Vivek Khemka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek Khemka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Khemka. The network helps show where Vivek Khemka may publish in the future.

Co-authorship network of co-authors of Vivek Khemka

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Khemka. A scholar is included among the top collaborators of Vivek Khemka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Khemka. Vivek Khemka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mercadé, T. Macarulla, Tanios Bekaii‐Saab, Kynan Feeney, et al.. (2025). 384TiP Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial. Annals of Oncology. 36. S147–S148.

Dańska-Bidzińska, Anna, Vanda Salutari, Ali̇ Ayhan, et al.. (2024). 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals of Oncology. 35. S561–S561. 1 indexed citations

Pignata, Sandro, Mariusz Bidziński, M.J. Rubio Pérez, et al.. (2024). 39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer. ESMO Open. 9. 103539–103539. 2 indexed citations

Marth, Christian, Richard D. Moore, Mariusz Bidziński, et al.. (2024). Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study. Gynecologic Oncology. 190. S63–S64.

Marth, Christian, Richard G. Moore, Mariusz Bidziński, et al.. (2024). #88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study. A570.2–A571. 7 indexed citations

Slomovitz, Brian M., David Cibula, Tayup Şimşek, et al.. (2022). KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS5623–TPS5623. 17 indexed citations

Slomovitz, Brian M., David Cibula, Murat Gültekin, et al.. (2022). TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma. A230.1–A230. 2 indexed citations

Friedman, Claire F., Paolo A. Ascierto, Diwakar Davar, et al.. (2020). 393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results. SHILAP Revista de lepidopterología. A239.1–A239. 5 indexed citations

Matrana, Marc, Frank Tsai, James M. Cleary, et al.. (2020). Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.. Journal of Clinical Oncology. 38(15_suppl). 3059–3059. 1 indexed citations

10.

Jankú, Filip, Ulka N. Vaishampayan, Vivek Khemka, et al.. (2018). Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors. Molecular Cancer Therapeutics. 17(1_Supplement). B176–B176. 3 indexed citations

11.

Jankú, Filip, Ulka N. Vaishampayan, Vivek Khemka, et al.. (2018). Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.. Journal of Clinical Oncology. 36(15_suppl). 2583–2583. 11 indexed citations

12.

Sarantopoulos, John, Muhammad Shaalan Beg, Josephine A. Taverna, et al.. (2018). A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS2612–TPS2612. 4 indexed citations

13.

Weiss, Glen J., Julia Beck, Donald P. Braun, et al.. (2017). Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clinical Cancer Research. 23(17). 5074–5081. 113 indexed citations

14.

Weiss, Glen J., Lisa Blaydorn, Julia Beck, et al.. (2017). Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investigational New Drugs. 36(1). 96–102. 163 indexed citations

15.

Weiss, Glen J., Lisa Blaydorn, Ashish Sangal, et al.. (2017). A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). British Journal of Cancer. 117(1). 33–40. 101 indexed citations

16.

Song, Louis M. Wong Kee, et al.. (2016). Endoscopic management of a gastrocolonic fistula. Gastrointestinal Endoscopy. 84(3). 525–526. 2 indexed citations

17.

Khemka, Vivek, et al.. (2016). P-278 Phase Ib/II study of nivolumab plus CAPIRI: Initial results of metastatic colon cancer and pancreatic adenocarcinoma patients. Annals of Oncology. 27. ii80–ii80. 3 indexed citations

18.

Weiss, Glen J., Robert P. Whitehead, Ashish Sangal, et al.. (2015). Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. OncoTargets and Therapy. 8. 959–959. 24 indexed citations

19.

Emanuel, Natalia, Melissa A. Simon, Michael Burt, et al.. (2010). Economic Impact of Terminal Illness and the Willingness to Change It. Journal of Palliative Medicine. 13(8). 941–944. 15 indexed citations

20.

Khemka, Vivek, et al.. (2008). A Sheep in Wolf’s Clothing. The American Journal of Medicine. 121(2). 107–109. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact